ABSTRACT
Affinity Chromatography .......................................................................... 236 9.3 Biomimetic Affinity Chromatography .................................................................. 238
9.3.1 Methods Based on Protein Structure ........................................................ 238 9.3.1.1 Biomimetic Dye-Ligands........................................................... 239 9.3.1.2 Chlorotriazine-Linked Synthetic
Biomimetic Ligands................................................................... 242 9.3.2 Combinatorial Approaches........................................................................ 244
9.3.2.1 Affinity Chromatographic Screening of Combinatorial Peptide Libraries ........................................... 245
9.3.2.2 Phage-Display Technology and Biopanning ............................. 247 9.3.2.3 Ribosome Display Technology.................................................. 247 9.3.2.4 SELEX ....................................................................................... 249
9.4 Summary and Conclusions ................................................................................... 251 Symbols and Abbreviations ............................................................................................ 251 References ....................................................................................................................... 252
9.1 INTRODUCTION
In the last 20 years, protein-based drugs have become significant weapons in the war against disease [1]. Approximately 1049 million grams of protein-based drugs were produced worldwide in 1999, and their production is expected to rise to 1150 million grams by 2004 [2]. Within a decade, it is estimated that approximately 25% of all drugs in developed countries will fall in this category, especially as the number of candidate therapeutic targets is increased [2].
